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Abstract
Background: Cancer-associated fibroblasts (CAFs) play an important role in cancer growth by interacting with
cancer cells, but their effects differ depending on the type of cancer. This study investigated the role of CAFs in biliary
tract cancers (BTCs), compared with pancreatic ductal adenocarcinoma (PDAC) as a comparison cohort.
Methods: We retrospectively evaluated alpha-smooth muscle actin (αSMA) expression in CAFs from 114 cases of
PDAC and 154 cases of BTCs who underwent surgical treatment at our institution from 1996 to 2017. CAFs were
isolated from resected specimens of BTC and PDAC, and tested for the effects of their supernatants and cytokines on
cancer cell proliferation.
Results: PDAC patients with positive αSMA expression showed significantly shorter overall survival and recurrencefree survival than αSMA-negative patients (p = 0.003, p = 0.009, respectively). BTC patients with positive αSMA
expression showed better recurrence-free survival than αSMA-negative patients (p = 0.03). CAF-conditioned medium
suppressed the proliferation of cancer cells for only OCUCh-LM1 cells and not PDAC cells. Blockage of Interleukin-8 (IL8) or its receptor C-X-C motif chemokine receptor 2 (CXCR2) by antibodies canceled the suppressive effect of the IL-8.
Conclusions: CAFs are a good prognostic factor in BTC, but not for PDAC. Moreover, CAF-produced Interleukin-8
suppresses the proliferation of OCUCh-LM1 cell lines.
Keywords: Bile duct cancers, Cancer-associated fibroblast, Interleukin-8, Pancreatic ductal adenocarcinoma,
Suppressive CAFs
Background
Biliary tract cancers (BTCs) are aggressive, and each has
a poor prognosis. Despite advance in surgical treatments
and chemotherapy that target cancer cells, their effects
are limited. Recently, therapies targeting non-cancerous
cells have been developed [1]. However, there are few
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reports on therapy that focus on tumor microenvironment, such as those of fibroblast in BTCs [2].
The stroma in solid tumors is composed of a rich extracellular matrix and many types of non-cancerous cells,
including fibroblasts, myeloid cells, and lymphocytes,
which play important roles in cancer growth [3]. Activated fibroblasts in the stroma, called cancer-associated
fibroblasts (CAFs), interact with cancer cells and are
involved in cancer progression, invasion, metastasis,
and resistance to anticancer drugs [4]. Carcinogenesis
of BTCs is closely associated with chronic inflammation
such as cholelithiasis, cholangitis, primary sclerosing
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cholangitis, and pancreaticobiliary maljunction [5, 6].
Fibroblasts in the tumor microenvironment are strongly
associated with the progression and metastasis of BTCs
[7]. However, there are few reports on the function of
CAFs in BTCs.
In scirrhous gastric cancer and pancreatic ductal adenocarcinoma (PDAC), which are characterized by abundant stroma component, CAFs secret several growth
factors, including transforming growth factor-beta,
hepatocyte growth factor and fibroblast growth factor [8,
9]. These cytokines from CAFs have been widely reported
to promote tumor progression, and alpha-smooth muscle actin (αSMA), fibroblast activation protein alpha,
and podoplanin have been reported as markers of CAFs.
On the other hand, Ozemir et al. and Rhim et al. each
reported that depletion of αSMA-positive CAFs promoted pancreatic cancer progression [10, 11]. More
recently, Mizutani et al. reported that meflin-positive
CAFs suppress cancer progression [12]. Research indicates that there are cancer-promoting CAFs and cancer-suppressive CAFs [13]. In addition, Yangngam et al.
reported that Interleukin (IL)-33 acts as a tumor suppressor against cholangiocarcinoma. They reported that high
IL-33 level in cancer cells and in CAFs is a good prognostic marker of survival. They revealed IL-33 inhibit cancer
cell migration [14]. Most cytokines in the tumor microenvironment have a promoting effect on cancer cells, but
some of them have shown a suppressive effect [10–14].
The purpose of this study was to investigate the role of
CAFs and to elucidate the interaction of cancer cells and
CAFs in BTCs by comparing them to PDAC cells, as a
control. Furthermore, we explored the factors secreted by
CAFs that suppress cancer progression.

Materials and methods
Patient population and tissue samples

This retrospective study includes 114 patients with PDAC
and 154 patients with BTCs who underwent surgical
treatment at our institution from 1996 to 2017. Clinical
data and formalin fixed paraffin-embedded tissues were
analyzed. BTCs include intrahepatic (n = 24), perihilar,
and distal bile duct cancer (n = 67), gallbladder cancer
(n = 27), and ampulla of Vater cancer (n = 36). Pathological findings were evaluated using TNM classification of
the UICC guideline, eighth edition [15]. After surgical
treatment, the patients were followed-up at 3–6-month
intervals by clinical examinations and enhanced computed tomography. Recurrence-free survival (RFS) and
overall survival (OS) were defined as the time from surgery to recurrence and death, respectively. The study was
conducted in accordance with the Declaration of Helsinki
and approved by the Ethics Committee of Osaka City
University (approval number: 924). Written informed
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consent were obtained from all patients for use of tissue
sample in this research.
Immunohistochemical determination

For immunohistochemical analysis, 4-μm thick sections
were obtained from the tissue microarray of formalin fixed
paraffin-embedded tissues. Immunohistochemical staining was examined. The sections were deparaffinized and
autoclaved for 10 min at 105 °C in Target Retrieval Solution
(Dako, Carpinteria, CA, USA). After blocking the endogenous peroxidase activity, the samples were incubated with
anti-human αSMA antibody (1:50, Dako, Carpinteria, CA,
USA) over night at 4 °C. The sections were then incubated
with biotinylated IgG for 10 min. The slides were treated
with streptavidin-peroxidase reagent, followed by counterstaining with Mayer’s hematoxylin. CAFs were located
around the cancer cells and stained brown. The staining
intensity of spindle-shaped cells in the stroma as well as
the stained area was evaluated on a 4 scale (0–3). Next, the
intensity score was summed up from the staining intensity
and the stained area. And then, the group of CAFs was
assigned 4 scales according to the intensity score (score
1 = no staining, 2 = weak, 3 = moderate, > 4 = strong).
Expression levels were considered positive when moderate
or strong staining, and negative when no or week staining.
Immunohistochemical evaluation was performed by two
independent investigators who were blinded to patient
outcomes and clinicopathological features.
Cell line and cancer associated fibroblast

In this study, six cell lines were used: two PDAC cell lines
(OCUP-A1, OCUP-A2) [16], two BTCs cell lines (OCUG,
OCUCh-LM1) [17, 18], HuCCT1 purchased from RIKEN
BRC (BioResource Research Center, Tsukuba, Japan), and
RBE purchased from RIKEN BRC (BioResource Research
Center). OCUP-A was established from anaplastic pancreatic adenocarcinoma. OCUG was established from
gallbladder cancer. OCUCh-LM1 was established from
a liver metastasis of extrahepatic bile duct cancer. These
four OCU series cell lines were established in Department
of Gastroenterological Surgery at Osaka City University
Graduate School of Medicine. CAFs were obtained and
isolated from specimens of pancreatic and distal bile duct
cancer that underwent surgical resection at our institution from 2017 to 2019. The specimens were sliced and
digested with collagenase (type I; Thermo Fisher Scientific,
MA, USA) at 37 °C for 4 h. After incubation, the specimens
with medium were put into a 50 ml tube through a sterile
cell strainer. The cell suspensions were spined down using
a centrifuge. Then the cells were collected and cultured
in Dulbecco’s modified Eagle medium (DMEM; Nikken,
Kyoto, Japan). To determine CAFs, immunohistochemical
staining was performed. Fibroblast cells were seeded into
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chamber slide and fixed with methanol for 10 min. They
were then incubated with anti-αSMA antibody (clone 1A4;
1:200; Dako, Cambridge, UK) for 1 h and counterstained
with Mayer’s hematoxylin. Cells with aSMA-positive were
determined as CAFs (Supplementary Fig. 1). All CAFs
used in the experiments were at less than 10 passages.
The BTC CAFs and PDAC CAFs were isolated from
different patients. The culturing medium consisted of
DMEM (Nikken, Kyoto, Japan) without serum. The cells
were cultured at 37 ̊C in 21% O2 for 24 hours in 10 mL
serum-free DMEM to obtain CAFs-conditioned medium
(CM-CAFs).
Cell proliferation assay

Each cell line was washed twice with phosphate-buffered saline and cultured at 5000 cells/well in 96 wells.
Each cell line was incubated in 50 μL of serum-free
DMEM and 50 μL of CM-CAFs for 3 days, and cell proliferation was evaluated using the CCK-8 cell counting kit
(Dojindo, Kumamoto, Japan). Recombinant human IL-8,
anti-human IL-8 antibody and anti-human C-X-C motif
chemokine receptor 2 (CXCR2) antibody (each from
R&D Systems, Minneapolis, MN, USA) were added to
100 μL of serum-free DMEM. After incubation for 3 days,
cell proliferation was evaluated using the CCK-8 and
MTT assay (Dojindo, Kumamoto, Japan). The control
medium contained 100 μL of serum-free DMEM.
Cytokine assay

The Human XL Cytokine Array Kit was purchased from
R&D Systems (Minneapolis, MN, USA) and experiments for measuring the cytokine content of the CAFsconditioned medium were performed according to the
manufacturer’s protocols. Complete list of Human XL
Cytokine Array Kit is in Supplementary Table 1.
Western blotting

Each cancer cell was lysed on ice to collect protein. Total
protein was quantified using Coomassie Plus Assay Kit
(Thermo Fisher Scientific). The protein was transferred to
a polyvinylidene difluoride membrane. The membranes
were placed in each primary antibody: CXCR2 (1:2000,
R&D Systems) or β-actin (1:5000; Sigma-Aldrich, St.
Louis, MO, USA) at 4 ̊C overnight. The membranes were
incubated with secondary antibody for 1 h and were
detected by enhanced chemiluminescence using ECL
prime (GE Health Care, Buckinghamshire, UK).
Statistical analysis

Continuous variables were compared using the MannWhitney U test. Categorical variables were compared
using chi-square or Fisher exact tests, as appropriate.
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OS and RFS were estimated using the Kaplan–Meier
method, and survival curves were compared using the
log-rank test. The groups were considered significantly
different at p < 0.05. All tests were performed using JMP
software version 13 (SAS Institute, Cary, NC, USA).

Results
Clinicopathological characteristics of PDAC and BTCs
with high and low αSMA expression

The clinicopathological characteristics of the 114
resected cases of PDAC and the 154 resected cases for
BTCs are listed in Tables 1 and 2. All patients were classified into an αSMA-positive or αSMA-negative expression group based on the defined criteria (Fig. 1). In
patients with PDAC, positive αSMA expression was not
associated with any clinicopathological characteristics
(Table 3). In patients with BTCs, positive αSMA expression was associated with T category (≤pT2), absence of
lymph node metastasis, absence of distant metastasis,
absence of lymphatic invasion, absence of neural invasion, UICC stage (≤ Stage 2), low serum CA19–9 levels
(Table 3).
Survival analysis

For patients with PDAC, those with positive αSMA
expression showed significantly shorter OS than those
with negative αSMA expression (median OS, 20.4
vs. 36.6 months; 5-year survival rate, 14.7 vs. 39.2%,
p = 0.003) (Fig. 2a). Similarly, the αSMA-positive group
showed statistically shorter RFS, compared to the αSMAnegative group (median RFS, 8.8 vs. 14.4 months; 5-year
RFS rate, 5.8 vs. 29.9%, p = 0.009) (Fig. 2b). On the other
hand, in the patients with BTCs, the αSMA-positive
group showed better RFS compared to the αSMAnegative group (median RFS: not reached vs 20.8 months;
5-year RFS rate: 39.9% vs 19.3%, p = 0.03) (Fig. 2d).
In the OS of patients with BTCs, the αSMA-positive
group tended to have better OS compared to the αSMAnegative group (median OS: 60.8 vs 29 months; 5-year
survival rate: 47.4% vs 31.5%, p = 0.06) (Fig. 2c).
Effect of CM‑CAFs on cancer cell proliferation

In order to evaluate the effect of CM-CAFs on cancer cell
proliferation, CM-CAFs from PDAC or BTC was added
to each cell line (OCUP-A1, OCUP-A2, OCUG and
OCUCh-LM1). Although none of the CM-CAFs affected
OCUP-A1 or OCUG cell proliferation, the BTC CMCAFs and PDAC CM-CAFs 1 and 2 promoted cell proliferation compared to OCUP-A2 growth in the control
medium. On the other hand, all CM-CAFs significantly
suppressed the proliferation of OCUCh-LM1 compared
to growth in the control medium (Fig. 3).
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Table 1 Clinicopathological characteristics of 114 patients with PDAC
number
Sex

men

58

women

56

differentiated

91

undifferentiated

16

Age, median (range)
Differentiated

70 (34–85)

other

7

Location of cancer

Head

68

Body/head

46

T category

pT1

6

pT2

23

pT3

82

pT4

3

Lymph node metastasis

absent

54

present

60

Distant metastasis

absent

106

present

8

Lymphatic invasion

absent

16

present

98

Vascular invasion

absent

67

present

47

Neural invasion

absent

18

present

96

UICC stage

1

17

2

86

3

3

4

8

Serum CEA level, ng/ml, median (range)

3.6 (0.5–262)

Serum CA19–9 level, U/ml, median (range)

98 (0–10,148)

Serum SPan-1 level, U/ml, median (range)

52 (1–2411)

Recurrence

yes

80

no

34

Outcome

death

75

alive

39

Recurrence free survival, days, median (range)

289 (0–5257)

Overall survival, days, median (range)

632 (26–1815)

PDAC pancreatic ductal adenocarcinoma, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, SPan1 s-pancreas-1 antigen

Cytokines contained in CM‑CAFs with inhibition effect

To determine the cytokine content of the CAFs that had
a suppression effect, cytokine assays were performed
on BTC CM-CAFs and PDAC CAFs 1 which had suppressed OCUCh-LM1 cell proliferation. The cytokines
commonly included were IL-8, IL-1α, and brain-derived
neurotrophic factor (BDNF) (Fig. 4a). For OCUCh-LM1,
the addition of IL-8 had a suppressive effect on proliferation. The addition of IL-1α promoted OCUCh-LM1 cell
proliferation. The addition of BDNF had no effect on
OCUCh-LM1 cell proliferation (Supplementary Fig. 2).

The addition of IL-8 did not affect cancer cell proliferation for OCUP-A1, OCUP-A2, OCUG, HuCCT-1, or
RBE (Supplementary Fig. 3). Both CCK and MTT assays
showed similar IL-8 suppressive effects on OCUCh-LM1
cells.
Effect of IL‑8 on cell proliferation of OCUCh‑LM1

To confirm the suppressive effect of IL-8 on OCUCh-LM1
cell proliferation, anti-human IL-8 antibody was
added to the cell culture medium. After the addition
of anti-human IL-8 antibody, the suppressive effect
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Table 2 Clinicopathological characteristics of 154 patients with BTCs
number
Sex

men

86

women

68

differentiated

123

undifferentiated

14

Age, median (range)
Differentiated

Location of cancer

T category

69 (43–87)

other

17

peripheral and distal bile duct

67

intrahepatic bile duct

24

gallbladder

27

ampullary

36

pT0

19

pT1

21

pT2

49

pT3

58

pT4

7

Lymph node metastasis

absent

98

present

49

Distant metastasis

absent

136

present

11

Lymphatic invasion

absent

60

present

64

Vascular invasion

absent

21

present

103

Neural invasion

absent

58

present

62

UICC stage

0

19

1

23

2

66

3

42

4

4

Serum CEA level, ng/ml, median (range)

2.6 (0–86.5)

Serum CA19–9 level, U/ml, median (range)

29 (0–45,152)

Recurrence

yes

76

no

78

Outcome

death

70

alive

84

Recurrence free survival, days, median (range)

521 (0–4160)

Overall survival, days, median (range)

778 (9–4157)

BTCs bile tract cancers, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19–9; carbohydrate antigen 19–9

of IL-8 disappeared. Anti-human CXCR2 antibody suppressed cell growth similar to that of the anti-human IL-8
antibody (Fig. 4b).
Expression of CXCR2 on cancer cell lines

Supplementary Fig. 4 showed that CXCR2 was expressed
on all cell lines, but the expression level was highest on
OCUCh-LM1.

Discussion
In this study, we found that CAFs that express αSMA
are a poor prognostic factor in patients with PDAC. On
the other hands, CAFs in BTCs were a good prognostic factor. In addition, we demonstrated in vitro that
IL-8 produced from CAFs suppresses the proliferation
of OCUCh-LM1 cells. Previous reports have indicated
that CAFs promote cancer growth by interacting with
cancer cells but are a poor prognostic factor in several
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Fig. 1 Immunohistochemical staining of αSMA. Microscopic images showing (a) negative, (b) weakly positive, (c) moderate positive, and (d)
strongly positive staining. Magnification is 200x, and the scale bar is 100 μm. The αSMA-positive CAFs in the stroma are stained brown. Each patient
is classified into either αSMA-positive or αSMA-negative expression group. Expressions are considered positive for scores of 2 or 3 and negative for
scores of 0 or 1. αSMA: alpha-smooth muscle actin, CAFs: cancer-associated fibroblasts

cancer types [19, 20]. CAFs often affect cancer progression by interacting with cancer cells via cytokines and
exosomes [8, 9]. The current result suggested that CAFs
have a one-sided effect on suppressing cancer progression in BTCs.
αSMA is the best-known marker for CAFs and has been
identified as a poor prognostic factor in several cancers
[21]. Akatsu et al. reported that αSMA-positive CAFs,
called type II CAFs, are associated with the endothelialto-mesenchymal transition and promote tumor growth
and metastasis [22]. Augsten reported that cancer-suppressive CAFs, type I CAFs, do not express αSMA, have
the ligand Slit2, and inhibit the tumorigenicity of cancer
cells [23]. The current study suggests that αSMA expression in CAFs is a good prognostic factor in BTCs, but not
in PDAC. This is the first report of αSMA-positive CAFs
in BTCs being a good prognostic factor.
We hypothesized that there were molecules, especially the cytokines secreted by αSMA-positive CAFs,
which might have a suppressive effect on the proliferation of OCUCh-LM1 cells. The results show that CMCAFs, which wither promoted proliferation or had no
effect in PDAC cells, showed a suppressive effect on

OCUCh-LM1 cell proliferation. More interestingly,
we found that both BTC CM-CAFs and PDAC CMCAFs contained factors that have suppressive effects
on OCUCh-LM1 cell proliferation. We previously
reported cytokines and exosomes are found in CMCAFs [8, 24]. In the current study, we demonstrated
that IL-8 secreted by CAFs suppresses OCUCh-LM1
cell proliferation.
The most interesting finding in this study was that
IL-8 produced from the CM-CAFs of PDAC and BTC
suppressed the proliferation of OCUCh-LM1 cells.
Although IL-8 is well known as inflammatory cytokines
[25], there are many reports of chemokines from CAFs
that promote the proliferation and migration of cancer cells [26, 27]. The function of IL-8 depends on its
interaction with its receptors, CXCR1 and CXCR2.
The CXCR1 receptors are activated only in response
to binding of IL-8, whereas CXCR2 receptors are activated by several chemokines [28]. Wang et al. reported
that CXCR1 expression correlates with drug resistance, invasion and metastasis in many types of cancers [29]. On the other hand, IL-8 and CXCR2 are also
involved in cell proliferation and cell senescence. CXCR2
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Table 3 Correlation between clinicopathological features and αSMA in 114 patients with PDAC and in 154 patients with BTCs
PDAC

Sex

Lymph node metastasis
Distant metastasis
Lymphatic invasion
Vascular invasion
Neural invasion
UICC stage
Serum CEA level
Serum CA19–9 level
Serum SPan-1 level

BTC

P value

αSMA

αSMA

αSMA

αSMA

positive

negative

positive n = 83

negative n = 71

n = 67

n = 47

men

37

21

46

40

women

30

26

37

31

Age, median (range)
T category

P value

0.26

0.26

68(34–85)

73(56–83)

0.06

70(43–87)

68(43–86)

0.23

pT0–2

20

9

0.19

56

33

a

pT3–4

47

38

27

38

absent

32

22

64

39

present

35

25

19

32

absent

61

45

81

62

present

6

2

2

9

absent

6

10

43

17

present

61

37

32

32

absent

38

29

66

37

present

29

18

9

12

absent

10

8

43

15

present

57

39

28

34

≦2

59

44

69

41

>2

8

3

14

30

< 5 ng/ml

38

29

63

56

≧5 ng/ml

27

18

14

10

< 37 U/ml

19

18

≧37 U/ml

48

29

< 30 U/ml

18

20

≧30 U/ml

48

27

0.92
0.31
0.06
0.59
0.76
0.31
0.72
0.26

52

28

28

37

0.008

a

0.003

a

0.01

a

0.01

0.06
a

0.001

a

< 0.001

0.62
a

0.008

0.09

αSMA alpha-smooth muscle actin, PDAC: pancreatic ductal adenocarcinoma, BTCs bile tract cancers, UICC Union for International Cancer Control, CEA
carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, SPan-1 s-pancreas-1 antigen
a

p < 0.05

is upregulated during senescence [30, 31]. We also
reported that CXCL1-CXCR2 signaling have tumor suppression roles in cholangiocarcinoma [32]. Therefore, it
may be that CXCR-2 is more involved than CXCR1 in
cancer suppression. Thus, we investigated IL-8/CXCR2
signaling. Here, we found that IL-8 produced from
CAFs suppresses the proliferation of OCUCh-LM1 cell
line. In addition, we demonstrated that the addition of
the antibodies that inhibit IL-8 or CXCR2 eliminated
their suppressive effect. Therefore, we suggest that IL-8/
CXCR2 signaling pathway might be a mechanism that
suppresses OCUCh-LM1 growth. However, CXCR2
expression was observed in each cell line suggesting that
even with the same receptor and signaling, the functions
of IL-8/CXCR2 signaling might be changed depending
on the difference in expression level of CXCR2 and the
characteristics of the cancer itself. In addition, the effect

of IL-8/CXCR2 signaling on cell senescence is needed in
the future.
There have been no reports of αSMA-positive CAF
in biliary tract cancer as a good prognosis factor of survival. This study revealed that anti-IL-8 antibody and
anti-CXCR2 antibody are able to inhibit the suppressive
effects of IL-8. However, these antibodies were not able
to inhibit the suppressive effects of CM-CAFs (data not
shown). This result indicated that the suppressive effect
came from not only IL-8 alone, but also several cytokines
produced by CAF. Also, the balance of chemokines and
the expression level of receptors were affected. Therefore,
further explorations are needed to achieve therapeutic
development.
This study has limitations. First, this was a retrospective study with a small cohort of patients. Second,
the number of CAFs and cell lines was low and limited.
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Fig. 2 Overall survival and recurrence-free survival according to αSMA in PDAC and BTCs. Kaplan-Meier survival curve indicates that αSMA-positive
PDAC patients show significantly shorter OS than those with αSMA-negative expression (a), with similar results for RFS (b). c Patients with
αSMA-positive expression tend to have better OS compared to those with αSMA-negative expression in BTCs. d BTC patients with αSMA-positive
expression show significantly better RFS compared to those with αSMA-negative expression. αSMA: alpha-smooth muscle actin, PDAC: pancreatic
ductal adenocarcinoma, BTCs: biliary tract cancers, OS: overall survival, RFS: recurrence-free survival

Fig. 3 Effect of CM-CAFs on proliferation of each cell line. Conditioned medium from each CAFs (CM-CAFs) significantly promote proliferation of
OCUP-A2 cells but significantly suppress proliferation of OCUCh-LM1. Data are presented as the mean and standard deviation of four experiments.
Asterisks indicate a significant difference. *p < 0.05. CAFs: cancer-associated fibroblasts
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Fig. 4 Cytokine array of CM-CAFs and effect of IL-8 on proliferation of OCUCh-LM1 cells. a Cytokine array compares BTC CM-CAFs and PDAC
CM-CAFs 1. BDNF, IL-8, and IL-1α are commonly included. b IL-8 significantly suppresses proliferation of OCUCh-LM1 cells. Addition of antibodies
against IL-8 or CXCR2 alleviates the suppression effect of IL-8. Each concentration of antibody is IL-8; 100 pg/100 μL, anti IL-8; 1000 pg/100 μL, anti
CXCR2; 1000 pg/100 μL, respectively. Data are presented as the mean and standard deviation of four experiments. Asterisks indicate a significant
difference from the control medium. *p < 0.05. CM-CAFs: Conditioned medium from cancer-associated fibroblasts, IL-8: Interleukin-8, BTCs:
biliary tract cancers, PDAC: pancreatic ductal adenocarcinoma, IL-1α: Interleukin-1α, BDNF: brain-derived neurotrophic factor, CXCR: C-X-C motif
chemokine receptor

Third, CAFs had a mixed population with αSMA
positive and negative fibroblasts, therefore, it was
unclear which type of CAFs had suppressive effects
on OCUCh-LM1 cell proliferation. Fourth, Human XL
Cytokine Array Kit could investigate only 105 typical
cytokines, so other cytokines might have been overlooked. Lastly, it is difficult to establish and passage
CAFs from biliary tract cancer and pancreatic cancer.
Therefore, it is also difficult to repeatedly experiment
with the same CAFs.
In summary, this study suggests that CAFs are a good
prognostic factor in patients with BTCs, but not in those
with PDAC. This is the first report of αSMA-positive
CAFs in BTCs being a good prognostic factor of survival.
In addition, IL-8 found in CM-CAFs suppresses the proliferation of OCUCh-LM1 cells. Our findings suggest
that CAFs have tumor-suppressive activity in BTCs via
their own humoral factors, including IL-8.
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